期刊文献+

吉西他滨联合多烯紫杉醇治疗蒽环类耐药转移性乳腺癌的疗效观察 被引量:4

下载PDF
导出
摘要 目的:观察吉西他滨(GEM)联合多烯紫杉醇(DXL)治疗蒽环类耐药转移性乳腺癌的临床疗效。方法:49例确诊为蒽环类耐药转移性乳腺癌患者,随机分为2组,联合组25例采用吉西他滨(GEM)联合多烯紫杉醇(DXL)治疗,对照组24例单纯使用多烯紫杉醇治疗。结果:2组近期疗效结果比较,GD联合组有效率为68.0%,对照组有效率为41.7%,2组在临床疗效上有统计学意义。49例患者2年随访率比较无显著性差异。2组患者的不良反应以血液学为主,其次为恶心、呕吐、腹泻、手足综合征等,患者均可以耐受这些不良反应。结论:吉西他滨(GEM)联合多烯紫杉醇(DXL)是治疗蒽环类耐药转移性乳腺癌的有效方案,且患者耐受性良好。
出处 《航空航天医学杂志》 2011年第8期982-983,共2页 Journal of Aerospace medicine
  • 相关文献

参考文献5

二级参考文献24

  • 1徐兵河.蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4):241-244. 被引量:85
  • 2Schuller J,Cassidy J,Dumont E,et al.Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients[J].Cancer Chemoher Pharmacol,2000,45(4):291-297.
  • 3Kurosumi M,Tabei T,Suemasu K,et al.Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients[J].Oncol Rep,2000,7(5):945-948.
  • 4Sawda N,Ishikawa T,Fukase Y,et al.Induction of thymidinephosphorylase activity and enhancement of capecitabine efficacy by Taxol Taxotere in human cancer xenografts[J].Clin Cancer Res,1998,4(4):1013-1019.
  • 5Pronk L C,Vasey P,Sparreboom A,et al.a phase and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumors[J].Br J Cancer,2000,83(1):22-29.
  • 6Wagstaff A J,Ibbotson T,Goa K L.Capecitabine:a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer[J].Drugs,2003,63 (2):217-236.
  • 7O'Shaughnessy J,Miles D,Vukclja S,et al.Superior survival with capecitabine plus docetaxcl combination therapy in an thracycline-pretreated patients with advanced breast cancer:phase Ⅲtrial results[J].J Clin Oncol,2002,20(12):2812-2823.
  • 8赵戬,陈慧书.临床医生GCP指南[M]人民卫生出版社,1997.
  • 9曹世龙.肿瘤学新理论与新技术[M]上海科技教育出版社,1997.
  • 10孙燕,周际昌.临床肿瘤内科手册[M]人民卫生出版社,1996.

共引文献93

同被引文献31

  • 1Ciruelos EM,Cort6s J,Cort6s-Funes H,et al. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial) [J]. Ann Oncol,2010,21 (7) : 1442-1447.
  • 2Bondarenko I, Gladkov OA, Elaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim : a randomized, mu|ticenter, active-control phase 3 trial in patients with breast cancer receiv- ing doxorubicin/docetaxel chemotherapy[J]. BMC Cancer,2013, 13(1):386.
  • 3Bianco AR, De Matteis A, Manzione L, et al. Sequen- tial epirubicin docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit 216 multi- center phase 1]] trial [J]. Proc Am Soc Clin Oncol, 2006, 24 . LBA520.
  • 4Jacquemier J, Penauh-Llorca F, Mnif H, et al. Identifi- cation of a basal like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS01 breast cancer trial 33 markers studied on tissue microar- rays(TMA) [J]. Proc Am Soc Clin Oncol, 2006,24 (18S) : Abstract 509.
  • 5Chitapanarnx I, Lorvdhava V, Kammendsupaphon P, et al. Gemcitabine plus cisplatin (GC) : a salvage regi men for advanced break cancer patients who have failed anthracycline and/or taxane therapy[J]. Can To Kagaku Ryoho,2006, 33(6) :761-766.
  • 6Somali I, Alacacioglu A, Tarhan MO, et al. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline- resistant metastatic breast cancer [J]. Chemotherapy, 2009,55(3) :155-160.
  • 7Nagourney RA, Flare M, Link J, et al. Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer[J]. Clin Breast Cancer, 2008,8 (5) : 432- 435.
  • 8史立波,李云涛,范忠林.蒽环类耐药转移性乳腺癌的治疗现状与思考[J].医学与哲学(B),2009,30(1):51-52. 被引量:4
  • 9张月秋,张海青,郭文斌.吉西他滨联合顺铂治疗复发转移性乳腺癌的疗效观察[J].当代医学,2009,15(9):130-131. 被引量:8
  • 10池桂玲,刘通,卢雨霖.吉西他滨联合顺铂治疗转移、复发性乳腺癌疗效观察[J].中国当代医药,2009,16(13):83-84. 被引量:1

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部